The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …

T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Naturally occurring CD4+ regulatory T cells (Tregs), which specifically express the
transcription factor FoxP3 in the nucleus and CD25 and CTLA-4 on the cell surface, are a …

Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

Regulatory T cells (Treg cells) are a small subset of immune cells that are dedicated to
curbing excessive immune activation and maintaining immune homeostasis. Accordingly …

One of the most exciting new therapies for cancer involves the use of autologous T cells that
are engineered to recognize and destroy cancerous cells. Patients with previously …

Adoptive immunotherapy with Tregs is a promising approach for preventing or treating type
1 diabetes. Islet antigen–specific Tregs have more potent therapeutic effects than polyclonal …

The broad success of adoptive immunotherapy to treat human cancer has resulted in a
paradigm shift in modern medicine. Modification of autologous and allogenic immune cells …

Genetically engineered T cell immunotherapies have provided remarkable clinical success
to treat B cell acute lymphoblastic leukaemia by harnessing a patient's own T cells to kill …